Cargando…
Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
Accumulation of amyloid beta can be visualized using [(18)F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [(18)F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease p...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826855/ https://www.ncbi.nlm.nih.gov/pubmed/29897009 http://dx.doi.org/10.1177/0271678X18783628 |
_version_ | 1783465190090604544 |
---|---|
author | Golla, Sandeep SV Verfaillie, Sander CJ Boellaard, Ronald Adriaanse, Sofie M Zwan, Marissa D Schuit, Robert C Timmers, Tessa Groot, Colin Schober, Patrick Scheltens, Philip van der Flier, Wiesje M Windhorst, Albert D van Berckel, Bart NM Lammertsma, Adriaan A |
author_facet | Golla, Sandeep SV Verfaillie, Sander CJ Boellaard, Ronald Adriaanse, Sofie M Zwan, Marissa D Schuit, Robert C Timmers, Tessa Groot, Colin Schober, Patrick Scheltens, Philip van der Flier, Wiesje M Windhorst, Albert D van Berckel, Bart NM Lammertsma, Adriaan A |
author_sort | Golla, Sandeep SV |
collection | PubMed |
description | Accumulation of amyloid beta can be visualized using [(18)F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [(18)F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 ± 6 years, Mini-Mental State Examination (MMSE): 23 ± 3) and eight controls (age: 63 ± 4 years, MMSE: 30 ± 0) were included. Ninety-minute dynamic positron emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection of 294 ± 32 MBq [(18)F]florbetapir. Several plasma input models and the simplified reference tissue model (SRTM) were evaluated. The Akaike information criterion was used to identify the preferred kinetic model. Compared to controls, Alzheimer’s disease patients had lower MMSE scores and evidence for cortical Aβ pathology. A reversible two-tissue compartment model with fitted blood volume fraction (2T4k_V(B)) was the preferred model for describing [(18)F]florbetapir kinetics. SRTM-derived non-displaceable binding potential (BP(ND)) correlated well (r(2 )= 0.83, slope = 0.86) with plasma input-derived distribution volume ratio. Test–retest reliability for plasma input-derived distribution volume ratio, SRTM-derived BP(ND) and SUVr((50–70)) were r = 0.88, r = 0.91 and r = 0.86, respectively. In vivo kinetics of [(18)F]florbetapir could best be described by a reversible two-tissue compartmental model and [(18)F]florbetapir BP(ND) can be reliably estimated using an SRTM. |
format | Online Article Text |
id | pubmed-6826855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68268552019-12-04 Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study Golla, Sandeep SV Verfaillie, Sander CJ Boellaard, Ronald Adriaanse, Sofie M Zwan, Marissa D Schuit, Robert C Timmers, Tessa Groot, Colin Schober, Patrick Scheltens, Philip van der Flier, Wiesje M Windhorst, Albert D van Berckel, Bart NM Lammertsma, Adriaan A J Cereb Blood Flow Metab Original Articles Accumulation of amyloid beta can be visualized using [(18)F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [(18)F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 ± 6 years, Mini-Mental State Examination (MMSE): 23 ± 3) and eight controls (age: 63 ± 4 years, MMSE: 30 ± 0) were included. Ninety-minute dynamic positron emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection of 294 ± 32 MBq [(18)F]florbetapir. Several plasma input models and the simplified reference tissue model (SRTM) were evaluated. The Akaike information criterion was used to identify the preferred kinetic model. Compared to controls, Alzheimer’s disease patients had lower MMSE scores and evidence for cortical Aβ pathology. A reversible two-tissue compartment model with fitted blood volume fraction (2T4k_V(B)) was the preferred model for describing [(18)F]florbetapir kinetics. SRTM-derived non-displaceable binding potential (BP(ND)) correlated well (r(2 )= 0.83, slope = 0.86) with plasma input-derived distribution volume ratio. Test–retest reliability for plasma input-derived distribution volume ratio, SRTM-derived BP(ND) and SUVr((50–70)) were r = 0.88, r = 0.91 and r = 0.86, respectively. In vivo kinetics of [(18)F]florbetapir could best be described by a reversible two-tissue compartmental model and [(18)F]florbetapir BP(ND) can be reliably estimated using an SRTM. SAGE Publications 2018-06-13 2019-11 /pmc/articles/PMC6826855/ /pubmed/29897009 http://dx.doi.org/10.1177/0271678X18783628 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Golla, Sandeep SV Verfaillie, Sander CJ Boellaard, Ronald Adriaanse, Sofie M Zwan, Marissa D Schuit, Robert C Timmers, Tessa Groot, Colin Schober, Patrick Scheltens, Philip van der Flier, Wiesje M Windhorst, Albert D van Berckel, Bart NM Lammertsma, Adriaan A Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title | Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title_full | Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title_fullStr | Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title_full_unstemmed | Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title_short | Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study |
title_sort | quantification of [(18)f]florbetapir: a test–retest tracer kinetic modelling study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826855/ https://www.ncbi.nlm.nih.gov/pubmed/29897009 http://dx.doi.org/10.1177/0271678X18783628 |
work_keys_str_mv | AT gollasandeepsv quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT verfailliesandercj quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT boellaardronald quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT adriaansesofiem quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT zwanmarissad quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT schuitrobertc quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT timmerstessa quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT grootcolin quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT schoberpatrick quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT scheltensphilip quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT vanderflierwiesjem quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT windhorstalbertd quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT vanberckelbartnm quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy AT lammertsmaadriaana quantificationof18fflorbetapiratestretesttracerkineticmodellingstudy |